Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.43 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.43 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.43 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 5/20 | 0.42 |
| ▸ | MMP9 | P14780 | 2/20 | 0.42 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | ENPP3 | O14638 | 1/20 | 0.42 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.42 |
| ▸ | RORC | P51449 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6828518 | 0.93 | MAPT (0.46) | MAPTPOLBRECQLMGLLSLC1A3 | |
| SCHEMBL6828538 | 0.88 | MGLL (0.51) | MAPTPOLBMGLLSLC1A3SLC1A2 | |
| SCHEMBL6828530 | 0.86 | RXFP1 (0.48) | MAPTMGLLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6828215 | 0.84 | MAPT (0.51) | MAPTPOLB | |
| SCHEMBL6828214 | 0.82 | MGLL (0.46) | MAPTMGLL | |
| SCHEMBL6828522 | 0.81 | THRB (0.45) | MAPT | |
| SCHEMBL6828202 | 0.80 | MAPT (0.46) | MAPTRECQLSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6825294 | 0.77 | TP53 (0.44) | MAPTPOLBMGLLSLC1A3SLC1A2 | |
| SCHEMBL6828206 | 0.77 | MAPT (0.47) | MAPTSLC1A3SLC1A2SLC1A1 | |
| SCHEMBL6828344 | 0.75 | MAPT (0.44) | MAPTRECQLSLC1A3SLC1A2SLC1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | claimed |
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | SUGEN, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138269-A1 | Substituted pyrroles as kinase inhibitors | PHKG1, PHKG2, MAP3K20 | MAPT 1856/4885POLB 1186/4885RECQL 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.